Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient

Seizure. 2020 Aug:80:157-158. doi: 10.1016/j.seizure.2020.06.008. Epub 2020 Jun 6.
No abstract available

Keywords: Covid-19; PRES; SARS-CoV-2; Status epilepticus; Verapamil.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anemia / etiology
  • Anticoagulants / therapeutic use
  • Anticonvulsants / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Calcium Channel Blockers / therapeutic use*
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / physiopathology*
  • Drug Combinations
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Lopinavir / therapeutic use
  • Lymphopenia / etiology
  • Male
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / physiopathology*
  • Posterior Leukoencephalopathy Syndrome / diagnostic imaging
  • Posterior Leukoencephalopathy Syndrome / etiology
  • Posterior Leukoencephalopathy Syndrome / physiopathology*
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Status Epilepticus / drug therapy*
  • Status Epilepticus / etiology
  • Verapamil / therapeutic use*

Substances

  • Anticoagulants
  • Anticonvulsants
  • Antiviral Agents
  • Calcium Channel Blockers
  • Drug Combinations
  • Enzyme Inhibitors
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Hydroxychloroquine
  • Verapamil
  • Ritonavir